Expert Interview
Discussing the potential of WAINUA (eplontersen) as an FDA approved treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy.
Ticker(s): AZN, IONSInstitution: SUNY Downstate Medical Center
- Director of the Muscular Dystrophy Association Clinic and Associate Professor of Neurology at SUNY Downstate Medical Center.
- Treats 8 patients with ATTR-PN, 15 patients for Friedreich’s Ataxia and 90 patients with myasthenia gravis.
- Research Interests in HIV-related neuropathy, inflammatory myopathies and has a clinical specialty in Neuromuscular disease.
To start us off, by way of introduction could you talk a little bit about your professional background and some details about your clinical practice?
Added By: sara_adminHow many patients do you treat for the TTR amyloidosis with cardiomyopathy?
Added By: sara_adminPhase III data was also recently presented. What were your thoughts on that so far?
Added By: sara_adminHow does the administration differ now with eplontersen?
I was wondering your thoughts on that and whether that's reliable or will the FDA allow this as the phase III program to go forward with the filing based on this?
The technology here is based on the antisense oligonucleotide as opposed to the RNA interference. Does that give you any concern in terms of potential side effect risks?
Added By: sara_adminWhat was the safety profile here? What was your impression of that?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
